Computed Tomography Use in Autosomal Dominant Polycystic Kidney Disease

Öz

Autosomal Dominant Polycystic Kidney Disease (ADPBD) is the most common inherited kidney disease. It is a systemic and progressive disease characterized by the formation and development of multiple cysts in the kidneys. The Mayo classification is widely used to determine the prognosis of ADPKD. Computed tomography (CT) can be used in this classification and may also be useful in revealing the common stone disease in ADPKD. 69 patients with ADPKD followed in the nephrology outpatient clinic were included in the study. CT scans of the patients taken during Mayo staging were examined. CT-based volume kidney volumes were calculated and evaluated in terms of cystic structures and nephrolithiasis. Glomerular filtration rates (eGFR) were calculated according to the CKD-EPI formula, and patients were screened for extra-renal signs of ADPKD. The mean age of the patients was 47±13 years, 45% (n=31) were female. Renal stones were detected in 34.8% (n=24) of the patients, and 25% of those with stones had bilateral nephrolithiasis. There was a significant negative correlation between total kidney volume and eGFR (r=-0.6, p<0.001). There was no difference in eGFR and total kidney volume between the group with and without stones, respectively, 87 (54-109) vs. 83 (49-106) ml/min/1.73m2 (p=0.805), 961 mm3 (695-1936) vs. 1219 mm3 (600-1663) (p=0.623). As a result, the use of CT in volume measurement for prognosis may provide an additional benefit in detecting kidney stones.

Anahtar Kelimeler

• ADPKD
• Nephrolithiasis
• Computed tomography
• Mayo staging

Otozomal Dominant Polikistik Böbrek Hastalığında Bilgisayarlı Tomografi Kullanımı

Öz

Otozomal Dominant Polikistik Böbrek Hastalığı (ODPBH), kalıtsal böbrek hastalıkları arasında en yaygın görülendir. Böbreklerde çok sayıda kist oluşumu ve gelişimi ile karakterize sistemik ve ilerleyici bir hastalıktır. ODPBH prognozunu belirlemede yaygın olarak Mayo sınıflandırması kullanılmaktadır. Bu sınıflamada kullanılan bilgisayarlı tomografi (BT), ODPBH’da sık görülen taş hastalığını ortaya çıkarmada da faydalı olabilir. Nefroloji polikliniğinde takip edilen 69 ODPBH’lı hasta çalışmaya dahil edildi. Hastaların Mayo evrelemesi yapılırken çekilen BT’leri incelendi. BT bazlı volüm böbrek hacimleri hesaplandı, kistik yapılar ve nefrolityasis açısından değerlendirildi. CKD-EPI formülüne göre glomerular filtrasyon hızları hesaplandı (eGFR), hastalar ODPBH’nın ekstra-renal bulguları açısından tarandı. Hastaların yaş ortalaması 47±13 yıl saptandı, %45’i (n=31) kadın cinsiyetindeydi. Hastaların %34.8’inde (n=24) böbrek taşı saptandı, taş olanların %25’i bilateral nefrolityazisdi. Total böbrek hacmi ile eGFR arasında anlamlı negatif korelasyon saptandı (r=-0.6, p<0.001). Taşı olan ve olmayan grup arasında eGFR ve total böbrek hacmi arasında farklılık saptanmadı, sırasıyla 87 (54-109) vs 83 (49-106) ml/dk/1.73m2 (p=0.805), 961 mm3 (695-1936) vs 1219 mm3 (600-1663) (p=0.623). Sonuç olarak prognoz belirleme için yapılan hacim ölçümlemesinde BT kullanımı böbrek taşlarını belirlemede ilave bir fayda sağlayabilir.

Anahtar Kelimeler

• : ODPBH
• Nefrolityazis
• Bilgisayarlı tomografi
• Mayo evrelemesi

Kaynakça

1. 1. Chebib FT, Torres VE: Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016. Am J Kidney Dis 2016, 67(5):792-810.
2. 2. Müller RU, Benzing T: Management of autosomal-dominant polycystic kidney disease-state-of-the-art. Clin Kidney J 2018, 11(Suppl 1):i2-i13.
3. 3. Sharma K, Caroli A, Quach LV, Petzold K, Bozzetto M, Serra AL, Remuzzi G, Remuzzi A: Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease. PLoS One 2017, 12(5):e0178488.
4. 4. Magistroni R, Corsi C, Martí T, Torra R: A Review of the Imaging Techniques for Measuring Kidney and Cyst Volume in Establishing Autosomal Dominant Polycystic Kidney Disease Progression. Am J Nephrol 2018, 48(1):67-78.
5. 5. Torres VE, Wilson DM, Hattery RR, Segura JW: Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1993, 22(4):513-519.
6. 6. Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE: Polycystic kidney disease. Nat Rev Dis Primers 2018, 4(1):50.
7. 7. Levine E, Grantham JJ: Calcified renal stones and cyst calcifications in autosomal dominant polycystic kidney disease: clinical and CT study in 84 patients. AJR Am J Roentgenol 1992, 159(1):77-81.
8. 8. Nishiura JL, Neves RF, Eloi SR, Cintra SM, Ajzen SA, Heilberg IP: Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol 2009, 4(4):838-844.

9. 9. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012, 367(25):2407-2418.
10. 10. Nadal Bosch J, Malcolm J, Moya M, Menowsky M, Dominici P: The Importance of Radiologic Imaging Modalities in Autosomal Dominant Polycystic Kidney Disease. Cureus 2022, 14(11):e31480.
11. 11. Bargagli M, Dhayat NA, Anderegg M, Semmo M, Huynh-Do U, Vogt B, Ferraro PM, Fuster DG: Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan. Clinical Journal of the American Society of Nephrology 2020, 15(7):1007-1014.
12. 12. Hogan MC, Norby SM: Evaluation and management of pain in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010, 17(3):e1-e16.
13. 13. Eroglu E, Kocyigit I, Cetin M, Zararsiz G, Imamoglu H, Bayramov R, Tastan S, Sipahioglu MH, Tokgoz B, Oymak O: Multiple urinary tract infections are associated with genotype and phenotype in adult polycystic kidney disease. Clinical and Experimental Nephrology 2019, 23(10):1188-1195.